Ivonescimab (20mg/kg Q3W)

DRUG3 trials

Sponsors

Sheng Zhang, Zhejiang Cancer Hospital, Sichuan University

Conditions

AK112Gastric CancerMultiple Advanced Tumors After PD-1 Therapy FailureRCTRadiationRectal Cancer

Phase 2

Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure

Not yet recruitingNCT07095803

Sheng ZhangMultiple Advanced Tumors After PD-1 Therapy Failure

Start: 2025-08-01End: 2027-02-01Target: 60Updated: 2025-07-31

SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer

Not yet recruitingNCT07162714

Zhejiang Cancer HospitalAK112, Radiation, Rectal Cancer

Start: 2025-09-01End: 2028-12-31Target: 30Updated: 2025-09-09

Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma

Not yet recruitingNCT07374250

Sichuan UniversityGastric Cancer, RCT

Start: 2026-02-01End: 2027-12-31Target: 154Updated: 2026-01-28